Pivotal Point Tracking Liquidia Technologies (LQDA): Biopharma Pioneer Settled Patent Disputes - Marketing of YUTREPIA Secured

Liquidia Technologies is a US biopharmaceutical company developing therapies for rare heart-lung diseases. On October 14, the stock jumped nearly 27% to $33.94. The trigger was a global settlement in the patent dispute with United Therapeutics. This clears the legal path for its main product YUTREPIA for the treatment of pulmonary arterial hypertension. In the third quarter of 2026, Liquidia achieved a preliminary product revenue of $222.7 million. The company benefits from its PRINT technology, which enables precise inhalable medications. With...